IRVINE, Calif., March 27, 2025 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (Nasdaq: BBNX), a pioneering leader in the development of advanced diabetes management solutions, today announced the appointment of Gerard Michel as an independent member of its board of directors, effective March 26, 2025. Mr.

加利福尼亚州欧文市，2025年3月27日（环球新闻社）——Beta Bionics, Inc.（纳斯达克股票代码：BBNX），作为先进糖尿病管理解决方案开发的先锋领导者，今日宣布任命杰拉德·米歇尔为公司董事会的独立董事，自2025年3月26日起生效。

Michel is Chief Executive Officer of Delcath Systems (Nasdaq: DCTH), a commercial-stage interventional oncology company..

米歇尔是Delcath Systems（纳斯达克股票代码：DCTH）的首席执行官，该公司是一家处于商业化阶段的介入肿瘤学公司。

“We are excited to welcome Gerard to the Beta Bionics Board,” said Sean Saint, President and Chief Executive Officer of Beta Bionics. “Gerard is a highly regarded leader in the pharmaceutical and medical technology industries, and brings deep experience in driving innovation and commercial success to our Board.

“我们非常高兴欢迎杰拉德加入 Beta Bionics 董事会，”Beta Bionics 总裁兼首席执行官肖恩·圣特表示。“杰拉德是制药和医疗技术行业备受推崇的领导者，为我们的董事会带来了推动创新和商业成功的深厚经验。

His contributions will be invaluable to Beta Bionics as we scale our commercial footprint and advance our innovation pipeline to simplify and alleviate the burden of managing diabetes.”.

他的贡献对于 Beta Bionics 来说将是无价的，因为我们正在扩大我们的商业版图，并推进我们的创新管道，以简化和减轻管理糖尿病的负担。”

Mr. Michel has over 30 years of experience in the pharmaceutical and medical technology industries across numerous functional areas. Prior to joining Delcath Systems as Chief Executive Officer in 2020, Mr. Michel served as Chief Financial Officer at Vericel Corporation, a biopharmaceutical company. Mr.

米歇尔先生在制药和医疗技术行业拥有超过30年的经验，涉足众多职能领域。在2020年加入Delcath Systems担任首席执行官之前，米歇尔先生曾在生物制药公司Vericel Corporation担任首席财务官。

Michel also served as Chief Financial Officer and Vice President, Corporate Development at Biodel, Inc. from November 2007 to May 2014, and Chief Financial Officer and Vice President of Corporate Development at NPS Pharmaceuticals Inc. from August 2002 to November 2007. Previously, Mr. Michel was a Principal at Booz Allen and held a variety of commercial roles at both Lederle Labs and Wyeth Labs.

米歇尔还曾在2007年11月至2014年5月期间担任Biodel公司的首席财务官和企业发展副总裁，并在2002年8月至2007年11月期间担任NPS制药公司的首席财务官和企业发展副总裁。在此之前，米歇尔先生是博思艾伦咨询公司的负责人，并在Lederle实验室和Wyeth实验室担任过多种商业职务。

Mr. Michel holds an M.S. in Microbiology from the University of Rochester School of Medicine, an M.B.A. from the Simon School of Business, and a B.S. in both Biology and Geology from the University of Rochester..

米歇尔先生拥有罗切斯特大学医学院的微生物学硕士学位、西蒙商学院的工商管理硕士学位，以及罗切斯特大学的生物学和地质学双学士学位。

About Beta Bionics

关于贝塔生物公司

Beta Bionics, Inc. is a commercial-stage medical device company engaged in the design, development, and commercialization of innovative solutions to improve the health and quality of life of insulin-requiring people with diabetes (PWD) by utilizing advanced adaptive closed-loop algorithms to simplify and improve the treatment of their disease.

Beta Bionics公司是一家商业阶段的医疗器械公司，致力于设计、开发和商业化创新解决方案，通过利用先进的自适应闭环算法来简化和改进胰岛素依赖型糖尿病患者的疾病治疗，从而改善他们的健康状况和生活质量。

The iLet Bionic Pancreas is the first FDA-cleared insulin delivery device that autonomously determines every insulin dose and offers the potential to substantially improve overall outcomes across broad populations of PWD. To learn more, visit .

iLet仿生胰腺是第一个获得FDA批准的胰岛素输送设备，它可以自主决定每次胰岛素剂量，并有潜力大幅改善广大糖尿病患者的整体健康状况。欲了解更多信息，请访问 。

www.betabionics.com

www.betabionics.com

.

。

Forward-Looking Statements

前瞻性声明

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements in this press release that are not statements of historical fact are forward-looking statements. Such forward-looking statements include, without limitation, statements regarding expectations of Beta Bionics, Inc.

本新闻稿包含1995年《私人证券诉讼改革法》意义上的前瞻性陈述。本新闻稿中的非事实性陈述为前瞻性陈述。此类前瞻性陈述包括但不限于对Beta Bionics公司预期的陈述。

(the “Company”), including Mr. Michel’s potential contributions to the Company; the timing, likelihood or success of the Company’s business strategy, including commercialization, as well as plans and objectives of management for future operations; and the Company’s anticipated growth. Words such as “believe,” “anticipate,” “plan,” “expect,” “intend,” “will,” “may,” “goal,” “potential” and similar expressions are intended to identify forward-looking statements, though not all forward-looking statements necessarily contain these identifying words.

（“公司”），包括米歇尔先生对公司的潜在贡献；公司业务战略的时机、可能性或成功，包括商业化，以及管理层对未来运营的计划和目标；以及公司预期的增长。“相信”、“预期”、“计划”、“预计”、“意图”、“将”、“可能”、“目标”、“潜力”等词语及相关表述旨在识别前瞻性陈述，但并非所有前瞻性陈述都一定包含这些识别词。

These forward-looking statements are based on the beliefs of the management of the Company as well as assumptions made by and information currently available to the Company. Such statements reflect the current views of the Company with respect to future events and are subject to known and unknown risks and uncertainties, including business, regulatory, economic and competitive risks and uncertainties about the Company, including, without limitation, risks inherent in developing product candidates, future results from the Company’s ongoing and future studies and clinical trials, the Company’s ability to obtain adequate financing to fund its product development and other expenses, risks that real-world data or future results may not be consistent with interim, initial or preliminary results or results from prior preclinical studies or clinical trials, trends in the industry, the Co.

这些前瞻性陈述基于公司管理层的信念以及公司目前可获得的信息和所做的假设。这些陈述反映了公司对未来事件的当前看法，并受到已知和未知风险及不确定性的影响，包括与公司相关的商业、监管、经济和竞争风险及不确定性，其中包括但不限于开发产品候选物固有的风险、公司正在进行和未来研究及临床试验的未来结果、公司获得足够融资以资助其产品开发和其他开支的能力、现实世界数据或未来结果可能与中期、初步或前期临床研究或临床试验结果不一致的风险、行业趋势以及公司相关风险。

Investor Relations:

投资者关系：

Blake Beber

布莱克·贝伯

Head of Investor Relations

投资者关系主管

ir@betabionics.com

ir@betabionics.com

Media and Public Relations

媒体与公共关系

:

：

Karen Hynes

凯伦·海恩斯

Vice President of Marketing

营销副总裁

media@betabionics.com

media@betabionics.com

Source: Beta Bionics, Inc.

来源：Beta Bionics公司。